http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2195106-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D521-00 |
| filingDate | 1995-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f7c2f7cc8bf7d236379ccf50dcc6e2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77d0b195088ef0505180e4d53ad290f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_108d6c0e06613d092ff89ec2e7c5c2db |
| publicationDate | 1996-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2195106-A1 |
| titleOfInvention | Indoline and azaindoline derivatives as 5-ht1d alpha receptor agonists |
| abstract | Compounds of formula (I), or a salt or prodrug thereof, wherein Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole; E represents a chemical bond or a straight of branched alkylene chain containing from 1 to 4 carbon atoms; Q represents a straight or branched alkylene chain containing from 1 to 6 carbon atoms; T represents nitrogen or CH; R1 represents aryl(C1-6)alkyl or heteroaryl(C1-6)alkyl, either of which groups may be optionally substituted; and R2 represents hydrogen or C1-6 alkyl are selective agonists of 5-HT1-like receptors, being potent agonists of the human 5-HT1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT1D.alpha. receptor subtype relative to the 5-HT1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5HT1D receptor agonists. |
| priorityDate | 1994-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 232.